PrBIMZELX® (bimekizumab injection) approved in Canada for treatment of moderate to severe hidradenitis suppurativa (HS) [Yahoo! Finance]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Yahoo! Finance
patients' disease activity globally compared to placebo at Week 16 with Hurley Stage II/III HS and inadequate response to antibiotics when treated with Pr BIMZELX ® (bimekizumab injection). OAKVILLE, ON Jan. 13, 2026 /CNW/ - UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for Pr BIMZELX ® (bimekizumab injection) indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) with an inadequate response to conventional systemic therapy. HS is a debilitating, chronic inflammatory skin disease characterized by recurrent and painful subcutaneous nodules, abscesses, and draining sinus tracts. New treatment options can help address a critical unmet need in hidradenitis suppurativa, empowering patients and clinicians with greater choice and hope for improved outcomes, " says Dr. Raed Alhusayen, MD, Dermatologist and HS specialist, Toronto, Canada. "At UCB Canada, we strive to make a material difference
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorderPR Newswire
- UCB shares leading scientific research and advances at American Epilepsy Society Annual MeetingPR Newswire
- UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)PR Newswire
- UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™PR Newswire